HBM Healthcare Investments publishes a net asset value per share (NAV) of CHF 285.53 as of March 31, 2022



After the record result of the previous year, HBM Healthcare Investments experienced a slight decline in value during the financial year 2021/22 ended March 31, 2022. The net asset value (NAV) per share fell by 3 .6% to CHF285.53. The share price fell disproportionately by 13.2% to CHF 276.00.

The healthcare sector presented a mixed picture in terms of performance during the year under review. While the MSCI World Health Care Index, which primarily tracks large-cap pharmaceutical and medtech companies, rose 13%, market capitalizations of biotech companies (Nasdaq Biotechnology Index -13% and SPDR S&P Biotech ETF -35%) decreased, in some cases significantly.

Based on the NAV as of March 31, 2022, HBM Healthcare Investments expects an annual loss of around CHF 80 million (previous year: annual profit of CHF 756 million). For an investment company, net income reflects changes in the value of equity interests held.

With a well-balanced mix of private and listed companies and cash and cash equivalents of over CHF 220 million, the portfolio remains well positioned for long-term value growth.

This result is preliminary and unaudited based on the current status of the closing process. The final annual result will be published on Friday May 6, 2022.

Source link


Comments are closed.